Coeptis Therapeutics (COEP) News Today

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

$0.37

0.00 (0.00%)

(As of 04/17/2024 ET)

Source

Source	Headline
	Short Interest in Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Grows By 171.3% americanbankingnews.com - April 11 at 1:03 AM
	Comparing Coeptis Therapeutics (COEP) and Its Peers americanbankingnews.com - April 9 at 1:56 AM
	Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award prnewswire.com - April 2 at 8:47 AM
	COEP Stock Earnings: Coeptis Therapeutics Beats EPS for Q4 2023 investorplace.com - April 1 at 11:03 AM
	Coeptis expands license for CAR technology to autoimmune diseases investing.com - February 28 at 11:49 PM
	Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK finance.yahoo.com - February 26 at 9:12 AM
	Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK prnewswire.com - February 26 at 9:00 AM
	Coeptis Therapeutics Holdings Inc Ordinary Shares COEP morningstar.com - February 17 at 5:31 PM
	Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections finance.yahoo.com - February 7 at 10:18 AM
	Coeptis Therapeutics Risks Nasdaq Delisting Over Bid Price msn.com - February 2 at 10:19 AM
	These are the 4 hottest stocks insiders bought in January insidertrades.com - January 29 at 2:00 PM
	Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024 finance.yahoo.com - January 4 at 9:52 AM
	Coeptis Therapeutics Stock (NASDAQ:COEP) Insider Trades benzinga.com - December 9 at 7:09 PM
	Coeptis Therapeutics to Present at the Emerging Growth Conference finance.yahoo.com - December 4 at 10:31 AM
	Buy Rating for Coeptis Therapeutics Holdings Amidst Promising Cancer Cell Therapy Platforms and Exclusive Licensing Assets markets.businessinsider.com - November 15 at 3:05 AM
	Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023 finance.yahoo.com - October 31 at 10:19 AM
	Coeptis Therapeutics to raise $2M in a private placement msn.com - October 24 at 10:45 AM
	Coeptis Therapeutics Announces $2 Million Private Placement finance.yahoo.com - October 24 at 10:45 AM
	Local pharma firm widens technology deal with the University of Pittsburgh bizjournals.com - October 11 at 4:16 PM
	Coeptis Expands License Agreement With University Of Pittsburgh To Include SNAP-CAR Platform markets.businessinsider.com - October 11 at 11:15 AM
	Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies finance.yahoo.com - October 9 at 10:31 AM
	Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting finance.yahoo.com - October 4 at 7:57 AM
	Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa finance.yahoo.com - September 27 at 12:15 PM
	Seattle biotech startup Deverra Therapeutics raising cash to develop cellular immunotherapies msn.com - September 20 at 1:29 AM
	Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection finance.yahoo.com - September 14 at 9:36 AM
	Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment finance.yahoo.com - September 11 at 9:00 AM
	Coeptis appoints Colleen Delaney as chief scientific and medical officer bizjournals.com - September 5 at 6:00 PM
	Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer finance.yahoo.com - August 30 at 5:34 PM
	Coeptics Flat on Deverra Deal baystreet.ca - August 17 at 10:11 AM
	Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics finance.yahoo.com - August 17 at 10:11 AM
	Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic finance.yahoo.com - August 1 at 3:24 PM
	Analysts Are Bullish on These Healthcare Stocks: Mirati Therapeutics (MRTX), Clearside Biomedical (CLSD) markets.businessinsider.com - July 21 at 4:49 PM
	Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering finance.yahoo.com - June 16 at 4:48 PM
	Coeptis Therapeutics Holdings, Inc. Announces Pricing Of $3.5M Underwritten Offering benzinga.com - June 14 at 10:15 AM
	Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten Offering finance.yahoo.com - June 14 at 10:15 AM
	EF Hutton Sticks to Its Buy Rating for Jasper Therapeutics (JSPR) markets.businessinsider.com - June 12 at 11:50 AM
	Coeptis Therapeutics to join Nasdaq Capital Market next Monday bizjournals.com - June 9 at 4:50 PM
	Coeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital Market finance.yahoo.com - June 9 at 11:50 AM
	Coeptis Therapeutics Shares Rally 67% In May, Clinical Interests And Planned Acquisitions Attract The Interest ($COEP) benzinga.com - May 30 at 7:46 AM
	Coeptis Therapeutics Appoints Brian Cogley as Chief Financial Officer finance.yahoo.com - May 17 at 12:55 PM
	JonesTrading Keeps Their Buy Rating on Coeptis Therapeutics Holdings (COEP) markets.businessinsider.com - May 11 at 6:45 PM
	Coeptis Therapeutics' SNAP-CAR Technology Platform for Programmable Antigen Targeting Featured in Peer-Reviewed Article in Nature Communications finance.yahoo.com - May 10 at 4:40 PM
	JonesTrading Initiates Coverage of Coeptis Therapeutics Holdings (COEP) with Buy Recommendation msn.com - April 19 at 7:44 PM
	Benzinga's Top Ratings Upgrades, Downgrades For April 19, 2023 msn.com - April 19 at 2:44 PM
	Coeptis Rises on Key Assets Acquisition from Deverra msn.com - April 18 at 7:34 PM
	Coeptis Therapeutics to acquire cell therapies from Deverra Therapeutics bizjournals.com - April 18 at 7:34 PM
	Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeutics finance.yahoo.com - April 18 at 9:12 AM
	Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), Coeptis Therapeutics Holdings (COEP) and Day One Biopharmaceuticals (DAWN) markets.businessinsider.com - April 5 at 10:03 AM
	EF Hutton Reiterates Buy on Coeptis Therapeutics, Maintains $6 Price Target benzinga.com - March 31 at 6:59 PM
	Should You Hold Coeptis Therapeutics Holdings Inc (COEP) Stock Monday Morning? benzinga.com - March 29 at 11:16 PM

Get Coeptis Therapeutics News Delivered to You Automatically

Bitcoin Rockets To Record High But Buy THIS Instead (Ad)

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

COEP Media Mentions By Week

COEP Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

COEP
News Sentiment
▼
-0.01

0.41
▲
Average
Medical
News Sentiment

COEP News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

COEP Articles
This Week
▼
0

0
▲
COEP Articles
Average Week

Get Coeptis Therapeutics News Delivered to You Automatically

Related Companies and Tools

Related Companies:

Headlines Tools:

This page (NASDAQ:COEP) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Coeptis Therapeutics (COEP) News Today

COEP Media Mentions By Week

COEP Media Sentiment

COEP News Coverage

Related Companies and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info